Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 9:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 8,150 matching trials from the live ClinicalTrials.gov search.
Conditions
Metastatic Colorectal Cancer
Interventions
Xilonix, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
57
States / cities
Birmingham, Alabama • Mobile, Alabama • Muscle Shoals, Alabama + 49 more
Conditions
Rectal Adenocarcinoma
Interventions
LY2157299, Capecitabine, Fluorouracil, Tumor specific mesorectal excision
Drug · Procedure
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Thoracic Neoplasms, Lung Neoplasms, Esophagus Neoplasms, Pleural Neoplasms, Thymus Neoplasms
Interventions
TOGA Tools
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
70 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Terminated Phase 4 Interventional Results available

Cimzia Versus Mesalamine for Crohn's Recurrence

NCT01696942
Conditions
Crohn's Disease
Interventions
Cimzia, Mesalamine
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
Rumination, Worry, Self-Criticism, Anxiety, Depression, Distress, Emotional
Interventions
Emotion Regulation Therapy via Telehealth
Behavioral
Lead sponsor
Teachers College, Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Colorectal Neoplasms, Digestive System Diseases, Colonic Diseases, Colorectal Cancer
Interventions
Stool Sample Collection Kit
Device
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
40 Years to 90 Years
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
21
States / cities
Newport Beach, California • Hamden, Connecticut • Holiday, Florida + 17 more
Conditions
Barrett's Esophagus, Gastroesophageal Reflux Disease
Interventions
Not listed
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Scottsdale, Arizona • Chicago, Illinois • Rockford, Illinois + 7 more
Suspended No phase listed Observational Accepts healthy volunteers

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NCT04031469
Conditions
Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
Interventions
There is no intervention in this study
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Ventura, California
Conditions
Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer
Interventions
INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2)
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2033
U.S. locations
30
States / cities
Duarte, California • Glendale, California • Los Angeles, California + 25 more
Conditions
Inflammatory Bowel Disease
Interventions
Biologically active human fecal material, OpenBiome
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Francisco, California
Conditions
Barrett's Esophagus, Neoplasms, Gastroesophageal Reflux
Interventions
Not listed
Lead sponsor
Midwest Biomedical Research
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2026
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Colorectal Cancer
Interventions
NKTR-102, irinotecan
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
9
States / cities
Peoria, Arizona • Burbank, California • Los Angeles, California + 6 more
Completed Not applicable Interventional Results available

Stoma Closure and Reinforcement Trial

NCT03750461
Conditions
Colon Cancer, Rectal Cancer, Ileostomy - Stoma
Interventions
Mesh Implantation
Device
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Metastatic Colorectal Adenocarcinoma, Metastatic Small Intestinal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Biopsy, Fecal Microbiota Transplantation, Fecal Microbiota Transplantation Capsule, Metronidazole, Neomycin, Nivolumab, Pembrolizumab, Questionnaire Administration, Vancomycin
Procedure · Drug · Biological + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Completed Not applicable Interventional Results available

Implementing Pharmacogenetic Testing in Gastrointestinal Cancers

NCT04736472
Conditions
Gastrointestinal Cancer
Interventions
Pharmacogenetic test
Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Lancaster, Pennsylvania • Philadelphia, Pennsylvania
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
35
States / cities
Chanute, Kansas • Dodge City, Kansas • El Dorado, Kansas + 22 more
Conditions
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Gastric Adenocarcinoma, Gastric Intestinal Type Adenocarcinoma, Gastric Mixed Adenocarcinoma, Recurrent Gastric Carcinoma
Interventions
Akt Inhibitor MK2206
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
186
States / cities
Mobile, Alabama • Fairbanks, Alaska • Tucson, Arizona + 124 more
Conditions
Crohn's Disease
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
35
States / cities
Scottsdale, Arizona • Oceanside, California • San Francisco, California + 31 more
Completed Phase 2 Interventional Results available

Study of GSK1363089 in Metastatic Gastric Cancer

NCT00725712
Conditions
Neoplasms, Gastrointestinal Tract
Interventions
GSK1363089 (formerly XL880)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 13 more
Conditions
Colorectal Cancer
Interventions
mutation analysis, tumor replication error analysis
Genetic
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
44
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 27 more
Conditions
Pyloric Stenosis
Interventions
Children with pyloric stenosis, Children without pyloric stenosis
Behavioral
Lead sponsor
Maimonides Medical Center
Other
Eligibility
2 Weeks to 9 Weeks
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Crohn's Disease
Interventions
PF-00547659 SC injection
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 75 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
69
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • La Jolla, California + 38 more
Conditions
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
MEK inhibitor MEK162, leucovorin calcium, fluorouracil, oxaliplatin, pharmacological study, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Duarte, California
Conditions
Rumination, Depressive Symptoms, Blood Pressure
Interventions
Rumination-Focused Cognitive Behavior Therapy
Behavioral
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky